Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Down 95.4% in April

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the recipient of a significant decline in short interest in April. As of April 30th, there was short interest totaling 3,057 shares, a decline of 95.4% from the April 15th total of 66,281 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 600,227 shares, the short-interest ratio is presently 0.0 days.

Analysts Set New Price Targets

Separately, Zacks Research raised Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy”.

Daiichi Sankyo Stock Up 5.0%

DSNKY stock traded up $0.82 during midday trading on Tuesday, reaching $17.33. 7,155 shares of the company were exchanged, compared to its average volume of 448,335. The company has a market cap of $32.83 billion, a price-to-earnings ratio of 15.90, a price-to-earnings-growth ratio of 0.85 and a beta of -0.25. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.69. Daiichi Sankyo has a 1-year low of $15.56 and a 1-year high of $28.21. The stock’s 50-day simple moving average is $17.84 and its 200 day simple moving average is $20.32.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its earnings results on Monday, May 11th. The company reported $0.15 earnings per share (EPS) for the quarter. Daiichi Sankyo had a net margin of 14.83% and a return on equity of 18.64%. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. On average, equities analysts forecast that Daiichi Sankyo will post 1.04 earnings per share for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody?drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.